PE firm buys GSK spinoff Neomed-Labs as it looks to ‘flip the next page’ of its story

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/anyaivanova)
(Image: Getty/anyaivanova)

Related tags: Gsk, Private equity, Ampersand Capital, PE, Lab research, Laboratory, Immunology

Neomed-Labs is aiming to double in size and become a global leader in clinical immunology lab services with an investment from Ampersand Capital.

The middle market private equity (PE) firm Ampersand Capital acquired the clinical immunology laboratory services provider Neomed-Labs from its not-for-profit founder and parent, the Neomed Institute.

The investment will be used to fuel both organic and inorganic growth initiatives, explained Mounia Azzi, chief business officer of Neomed-Labs.

According to the company – which was formed in April 2015 as a spinoff from GSK’s Clinical Laboratory Services unit – in addition to expanding its presence in Quebec, it also will pursue expansion into adjacent markets and geographies.

Azzi said the rationale behind the deal is “to flip the next page of our story after three years as a subsidiary of a non-for-profit organization whose mandate is clearly not to be a shareholder in health care service provider companies.”

“Partnering with a health care mid-market reference private equity group will enable us to fund organic and inorganic initiatives required to become the obvious global leader in clinical immunology lab services,”​ she told us.

As per next steps in the company’s evolution, Azzi said the it is “quite realistic”​ that it could double its size organically in 24 months based on the current backlog and client base.

Neomed-Labs also will look to add services to its portfolio, “so that we can tackle other clinical immunology opportunities than infectious vaccines, currently our core business,”​ she explained.

Ampersand’s current portfolio of includes several service providers, such as Brammer Bio​, Avista Pharma​, bioventus, MedPharm, KeyBiologics, among others.

Related news

Show more

Related products

Flow Cytometry Services

Flow Cytometry Services

Q2 Solutions | 01-Jun-2020 | Data Sheet

We are an established leader in flow cytometry services for clinical trials. Our technologies and solutions meet the growing global demand for enhanced...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more